Our Team

Management Team

David Platt
CEO & Chairman
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.
Ola Soderquist
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC). Ola is a multi-lingual senior finance professional poised to work globally and cross-functionally, particularly with complex projects involving business integration, systems implementation, continuous improvement, and process excellence. Ola’s managerial experience portfolio includes; Start-ups, Private, Public, Venture Capital and Private Equity ownership. He obtained a BS and an MS in Accounting from Stockholm School of Economics and an MBA from Babson College – Franklin W. Olin Graduate School of Business.
Mike Sheikh
EVP Business Development
Mr. Sheikh worked as a Broker and eventually Research Analyst at Dean Witter and National Securities. He is a long-time Biotech Consultant expertise for public or private biotech companies with disruptive technologies. Mr. Sheikh the founder of Falcon Strategic Research. Mike has a BS in Economics and is a US Air Force Academy graduate and pilot.

Board of Directors

Hana Chen-Walden
Dr. Chen-Walden has specialized in regulatory affairs in the pharmaceutical industry in the US and Europe. She has thirty years of regulatory experience in EMEA and in individual European countries. Since 2004, She has consulted for the European Clinical and Regulatory Consultancy in medical monitoring, quality assurance, and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases, and medical devices. From 2000 to 2003, Dr. Chen-Walden was Director of International Regulatory Affairs, Covalent Group Ltd. From 1997 to 2000, she was Medical, Drug Safety, and Regulatory Director at CRC, a clinical contract research organization in France. Dr. Chen-Walden received her MD degree from the University of Tel Aviv, Israel. She has practiced medicine in Germany and France.
Anders N. Utter
Financial Expert
Mr. Utter has more than 25 years of finance, accounting and management experience in medical devices, consulting and manufacturing industries in capacities as CFO, Controller and Managing Director. He had progressively increased management experience in the European Nolato Group and later on in the Amplex Group. Mr. Utter has had a broad business exposure with IFRS and GAAP reporting as well as with SOX compliance. He has also worked with M&A evaluations, financing and integration as well as more hands-on manufacturing cost accounting and reporting. He is currently in charge of the finance control at one of General Cable’s entities. Mr. Utter is and has been serving as a director on boards in both profit as well as non-profit organizations. Mr. Utter holds an MBA from Babson College and a BA from Uppsala University in Sweden.
Alan M. Hoberman
Alan M. Hoberman, PhD is president and CEO of Argus International, Inc., overseeing a staff of scientists and other professionals who provide consulting services for industry, government agencies, law firms, and other organizations, both in the U.S. and internationally. Between 1991 and 2013 he held a series of positions of increasing responsibility at Charles River Laboratories Preclinical Services (formerly Argus Research Laboratories, Inc.), most recently as Executive Director of Site Operations and Toxicology. He currently works with that organization to design, supervise, and evaluate reproductive and developmental toxicity, neurotoxicity, inhalation, and photobiology studies. Dr. Hoberman holds a PhD in toxicology from Pacific Western University, an MS in interdisciplinary toxicology from the University of Arkansas, and a BS in biology from Drexel University.
Dale H. Conaway
We are proud to have Dr.Dale H. Conaway as a board member at Bioxytran Inc. From 1998 to 2001, Dr. Conaway served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture. From 1994 to 1998, he was Regulatory Affairs Manager for the Michigan Department of Public Health Vaccine Production Division. From May 2001 to February 2009, Dr. Conaway was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. Dr. Conaway received a DVM degree from Tuskegee Institute and an MS degree in pathology from the College of veterinary medicine at Michigan State University.

Advisory Board

Dr. Thomaskutty Alumparambil
Scientific Advisory Board
B.S., C.C.P
Dr. Thomaskutty Alumparambil. B.S., C.C.P has over 30 years of clinical experience that includes heart, lung, and liver transplants. He is an expert on quality control and quality assurance programs, surgical protocols, blood gas analysis and anticoagulation management.
Dr. Alben Sigamani
Scientific Advisory Board
Dr. Alben Sigamani, MD. Dr.Sigamani is currently Professor and Head of Clinical Research, Narayan Health, Bangalore. He has over 17 years of experience in clinical research and in managing multi-center academic and regulatory Randomized Controlled Trials in India. He has several publications to his credit with a citation index (h-index) of 24. Dr. Sigamani is a Medical Professional (MD) in Clinical Pharmacology & Therapeutics with a Masters Degree in Clinical Trials from the University of London. In 2020, Dr. Sigamani obtained “COVID-19: Tracking The Novel Coronavirus Certificate ” from the London School of Hygiene and Tropical Medicine.
Prof. Avraham Mayevsky
Scientific Advisory Board
Prof. Avraham Mayevsky is a worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology. Prof. Mayevsky is a professor at the Faculty of Life Sciences, Bar-Ilan University, Israel. He founded Vital Medical Ltd. He served as Head of the Department of Life Sciences and Dean of the Faculty of Natural Sciences at Bar-Ilan University, where he established a center of tissue physiology. He served as Visiting professor at University of Pennsylvania and Johns Hopkins Medical School World-recognized expert in tissue physiology, especially in brain metabolism. He Published over 150 papers and patents. He has published over 170 papers in scientific journals and is the author of five patents. Prof. Mayevsky completed PhD from Weizmann Institute of Science, Rehovot, Israel.